Mr. Nilmadhab Roy | Medicine | Young Scientist Award 

Mr. Nilmadhab Roy | Medicine | Ph. D. Scholar at Vellore Institute of Technology | India

Mr. Nilmadhab Roy is a dedicated chemical sciences researcher recognized for his growing contributions to coordination chemistry, metallodrug design, and advanced photodynamic therapeutic systems. He holds solid academic training in chemistry, supported by postgraduate qualifications and advanced research coursework that strengthened his foundation in inorganic chemistry, medicinal chemistry, and organometallic synthesis. Throughout his professional experience, Mr. Nilmadhab Roy has been associated with reputed research laboratories where he gained hands-on expertise in designing metal-based complexes, fluorescence imaging tools, ligand engineering, and mechanistic exploration of anticancer agents. His research interests include the synthesis of ruthenium, iridium, and rhenium complexes, development of luminescent biomolecular probes, theranostic platforms, mitochondrial-targeting agents, and redox-modulating metallotherapeutics for cancer treatment. He possesses strong research skills in experimental inorganic chemistry, spectroscopy, cell-based assays, molecular docking, imaging analysis, and structure–activity relationship evaluation. His collaborative projects often involve multidisciplinary teams focusing on targeted drug delivery, cancer theranostics, organelle-specific therapy, and mechanistic biochemical interactions. Mr. Nilmadhab Roy has co-authored several high-impact publications in internationally indexed journals, including Coordination Chemistry Reviews, Inorganica Chimica Acta, Polyhedron, Dalton Transactions, and ACS Omega, demonstrating his strong scientific judgment and experimental rigor. His work has earned increasing citations and recognition from researchers worldwide, reflecting his contribution to the advancement of next-generation metallopharmaceuticals. He has also participated in academic conferences, research workshops, and institutional scientific programs that enhanced his leadership, teamwork, and knowledge-dissemination skills. Mr. Nilmadhab Roy continues to explore innovative routes in organelle-specific targeting, luminescent metal complexes, and anticancer mechanisms, aiming to contribute to the evolution of safe, effective, and sustainable therapeutic materials. His academic discipline, research productivity, and commitment to scientific advancement position him as a promising young researcher with substantial potential for future innovations in inorganic medicinal chemistry.

Profile: Google Scholar

Featured Publications

1. Kar, B., Das, U., Roy, N., & Paira, P. (2023). Recent advances on organelle specific Ru(II)/Ir(III)/Re(I) based complexes for photodynamic therapy. 92 citations.

2. Sharma, A., Sudhindra, P., Roy, N., & Paira, P. (2020). Advances in novel iridium (III) based complexes for anticancer applications: A review. 77 citations.

3. Pete, S., Roy, N., Kar, B., & Paira, P. (2022). Construction of homo and heteronuclear Ru(II), Ir(III) and Re(I) complexes for target specific cancer therapy. 46 citations.

4. Sudhindra, P., Sharma, S. A., Roy, N., Moharana, P., & Paira, P. (2020). Recent advances in cytotoxicity, cellular uptake and mechanism of action of ruthenium metallodrugs: A review. 44 citations.

5. Kar, B., Roy, N., Pete, S., Moharana, P., & Paira, P. (2020). Ruthenium and iridium based mononuclear and multinuclear complexes: A breakthrough of next-generation anticancer metallopharmaceuticals. 43 citations.

6. Sarkar, B., Mondal, A., Madaan, Y., Roy, N., Moorthy, A., Kuo, Y. C., & Paira, P. (2019). Luminescent anticancer ruthenium (II)-p-cymene complexes of extended imidazophenanthroline ligands: Synthesis, structure, reactivity, biomolecular interactions and live cell studies. 43 citations.

7. Mondal, A., Sen, U., Roy, N., Muthukumar, V., Sahoo, S. K., & Bose, B., et al. (2021). DNA targeting half sandwich Ru(II)-p-cymene-N^N complexes as cancer cell imaging and terminating agents: Influence of regioisomers in cytotoxicity. 41 citations.